vimarsana.com
Home
Live Updates
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program : comparemela.com
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
Week 96 Phase 2b HARMONY Results for Treatment of Patients with Pre-Cirrhotic NASH/MASH to be Reported in March 2024 End-of-Phase 2 FDA Meeting Scheduled for the first quarter of 2024 to Review...
Related Keywords
United States ,
Americans ,
Kitty Yale ,
Austin Murtagh ,
Sarah Oconnell ,
Twitter ,
Exchange Commission ,
Linkedin ,
Nasdaq ,
Meeting Scheduled ,
Preview Phase ,
Regulatory Path ,
Decompensated Cirrhosis ,
South San ,
Private Securities Litigation Reform Act ,
Annual Report ,
Quarterly Report ,
Markets ,
comparemela.com © 2020. All Rights Reserved.